Gastroenterology & Hepatology Research

Torres profile photo

Innovative Research

Our physician scientists and clinical investigators are leading the way in enhancing the prevention, diagnosis, and treatment of gastrointestinal and hepatology diseases through their research.

Our Research

The U-M Medical School Department of Internal Medicine Division of Gastroenterology and Hepatology has a long tradition of excellence and national leadership in basic science and clinical research and is consistently among the top divisions funded by the National Institutes of Health.

Continuing in this tradition, our division conducts cutting-edge investigations into the molecular, cellular, and physiological conditions of normal and disease states of the gastrointestinal tract, liver, and pancreas, and state-of-the-art clinical research ranging from hepatitis C to Wilson Disease. 

Advanced training and collaborative research involving faculty, fellows, medical students, and graduate students enhance our research endeavors to discover cures and improve clinical outcomes.
stidham-ryan

Clinical & Research Programs

The Division of Gastroenterology and Hepatology is home to multiple nationally-recognized clinical and research programs.

Learn More About Our Programs

GI & Hepatology Research

Learn more about the Division of Gastroenterology and Hepatology research.

Get to know our faculty and their research

Gut Talk, on Healio Gastroenterology, is a podcast hosted by Dr. Sameer Berry and Dr. William Chey that explores the impact of health policy, technology, practice management, and research on the field of gastroenterology. Listen to the podcast.

T32 Training Programs

Our three-year GI Fellowship Training Program prepares fellows for careers in academic medicine and is separated into three tracks, including two NIH-funded tracks:

  1. NIH-funded T32 Clinical Research track (“Gastroenterology/Research-Outcomes” – NRMP Program Code 1293144F2)
  2. NIH-funded T32 Basic/Translational Research track (“Gastroenterology/Basic Science Research” – NRMP Program Code 1293144F1)

Learn more about the GI fellowship

Featured News & Stories

 See all news particles forming colorful in intestines
Health Lab

IBS treatment response predicted by gut microbiome in new study

A Michigan Medicine study finds the low FODMAP diet and the antibiotic rifaximin provided similar and significant relief for patients with irritable bowel syndrome with diarrhea (IBS-D).
 red cells clustered together inside body black light up blue see through
Health Lab

Understanding esophageal cancer

In this Q&A, a Michigan Medicine doctor talks about esophageal cancer, its signs and risk factors to know.
 Man in a blue pullover against the background of Michigan Stadium
Health Lab

Thriving after a rectal cancer diagnosis

Kyle Kipke was diagnosed with rectal cancer and received chemotherapy and radiation as treatment at Michigan Medicine.
 close up microscopic grey close up
Health Lab

FDA-approved cancer drug fedratinib reshapes how cell organelles communicate, providing new therapeutic avenues

University of Michigan researchers found that the FDA-approved drug fedratinib can lead to endoplasmic reticulum and mitochondria contact site formation, providing a potential therapeutic avenue.
 intestines red with red dot
Health Lab

Colorectal cancer is no longer just a disease of older adults

With colorectal (CRC) on the rise in younger patients, a specialist in gastroenterology and human genetics discusses why that may be and what to look for.
 microscope drawing yellow navy
Health Lab

Glucose drives STAT3 activation in colorectal cancer cells, leading to tumor growth

University of Michigan researchers have shown that glucose levels sustain the increased STAT3 activation in colorectal cancer cells. Their findings suggest that targeting glucose metabolism could inhibit STAT3, leading to novel therapeutic strategies.